RCUS Share Price | Arcus Biosciences, Inc. Stock Analysis & Recommendation

Q: How big is Arcus Biosciences, Inc.?

Market Cap: As of Jun 18, Arcus Biosciences, Inc. has a market capitalization of 921.20 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Arcus Biosciences, Inc. reported net sales of 141.00 million and a net profit of -391.00 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 485.00 million and total assets of 1,150.00 million.

Q: What does Arcus Biosciences, Inc. do?

Overview: Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapy within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Most recent Net Sales: 28 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -112 Million (Quarterly Results - Mar 2025) Market cap: USD 921.20 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.76 Return on Equity: -73.63% Price to Book: 1.73Contact Details: Address: 3928 Point Eden Way, HAYWARD CA: 94545-3719 Tel: 1 510 6946200 Website: https://www.arcusbio.com/

Q: Is Arcus Biosciences, Inc. overvalued or undervalued?

As of 28 February 2023, the valuation grade for Arcus Biosciences, Inc. moved from attractive to risky, indicating a shift towards a more concerning outlook. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 1.99 and an EV to Sales ratio of 0.84, which suggest that the market is pricing the stock higher than its underlying value. Additionally, the negative ROE of -73.63% further underscores the company's struggles in generating returns for shareholders.In comparison to peers, Arcus Biosciences has a significantly worse P/E ratio of -4.0858, while Arcellx, Inc. and CymaBay Therapeutics, Inc. report P/E ratios of -20.9783 and -35.3832, respectively, indicating that Arcus is not the worst performer but still faces substantial challenges. The company's recent stock performance has been poor, with a year-to-date return of -16.45%, contrasting sharply with the S&P 500's positive return of 12.22% during the same period, highlighting the underperformance of Arcus relative to the broader market.

Q: Is Arcus Biosciences, Inc. technically bullish or bearish?

As of 26 September 2025, the technical trend for Arcus Biosciences, Inc. has changed from sideways to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show a mildly bearish signal on that same timeframe. The KST is bullish weekly but bearish monthly, while the Dow Theory and OBV both indicate a mildly bullish trend on both weekly and monthly periods.In terms of performance, Arcus has outperformed the S&P 500 over the past week and month, with returns of 3.63% and 23.70% respectively, compared to the S&P 500's -0.31% and 2.75%. However, the longer-term returns are significantly negative, with a year-to-date return of -13.77% versus the S&P 500's 12.96%, and a 3-year return of -47.63% compared to 81.77% for the index.Overall, the current technical stance is bullish, but the strength is mixed due to the divergence in longer-term indicators.

Results Declared: Arcus Biosciences, Inc. has declared results on 25 Feb 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.35 M

Shareholding (Dec 2025)

FII

12.41%

Held by 110 FIIs

DII

33.08%

Held by 41 DIIs

Promoter

29.29%

How big is Arcus Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Arcus Biosciences, Inc. has a market capitalization of 921.20 million, with net sales of 141.00 million and a net profit of -391.00 million over the latest four quarters. The company reported shareholder's funds of 485.00 million and total assets of 1,150.00 million as of Dec 24.

View full answer

What does Arcus Biosciences, Inc. do?

22-Jun-2025

Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer immunotherapy, with a market cap of $921.20 million and recent net sales of $28 million, but a net loss of $112 million. The company does not currently pay dividends and has negative key financial metrics.

View full answer

Who are in the management team of Arcus Biosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Arcus Biosciences, Inc. includes Dr. Terry Rosen (CEO), Dr. Juan Jaen (President), and several directors including Dr. Yasunori Kaneko and Dr. David Lacey, among others, who oversee the company's strategic direction and operations.

View full answer

Is Arcus Biosciences, Inc. overvalued or undervalued?

20-Sep-2025

As of February 28, 2023, Arcus Biosciences, Inc. is considered risky due to overvaluation indicated by negative financial metrics, including a Price to Book Value of 1.99, an EV to Sales ratio of 0.84, a negative ROE of -73.63%, and a poor year-to-date stock performance of -16.45% compared to the S&P 500's 12.22% return.

View full answer

Is Arcus Biosciences, Inc. technically bullish or bearish?

30-Sep-2025

As of September 26, 2025, Arcus Biosciences shows a bullish technical trend with mixed strength indicators, having outperformed the S&P 500 recently but significantly underperformed over the longer term.

View full answer

Compare Arcus Biosciences, Inc. with Similar Stocks

AbCellera Biologics, Inc.Zentalis Pharmaceuticals, Inc.CymaBay Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROE of 1.44%

The company has been able to generate a Return on Equity (avg) of 1.44% signifying low profitability per unit of shareholders funds

The company has declared negative results for the last 2 consecutive quarters

Risky - Negative EBITDA

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,350 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.65

Return on Equity

-78.21%

Price to Book

5.39

Revenue and Profits:

Net Sales:

33 Million

(Quarterly Results - Dec 2025)

Net Profit:

-106 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-2.86%

6 Months

112.35%

1 Year

146.67%

2 Years

28.46%

3 Years

47.55%

4 Years

-26.22%

5 Years

-37.4%

Arcus Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

25.28%

EBIT Growth (5y)

-216.85%

EBIT to Interest (avg)

-91.46

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.76

Sales to Capital Employed (avg)

0.34

Tax Ratio

0.26%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

1.44%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.39

EV to EBIT

-3.13

EV to EBITDA

-3.22

EV to Capital Employed

-4.18

EV to Sales

4.04

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-54.28%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 61 Schemes (25.16%)

Foreign Institutions

Held by 110 Foreign Institutions (12.41%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 26.92% vs -83.75% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 21.48% vs 0.00% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "33.00",
          "val2": "26.00",
          "chgp": "26.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-111.00",
          "val2": "-140.00",
          "chgp": "20.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "3.00",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-106.00",
          "val2": "-135.00",
          "chgp": "21.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,454.50%",
          "val2": "-5,461.50%",
          "chgp": "200.70%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -4.26% vs 120.51% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -24.73% vs 7.82% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "247.00",
          "val2": "258.00",
          "chgp": "-4.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-376.00",
          "val2": "-300.00",
          "chgp": "-25.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "8.00",
          "val2": "4.00",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-20.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-353.00",
          "val2": "-283.00",
          "chgp": "-24.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,562.80%",
          "val2": "-1,201.60%",
          "chgp": "-36.12%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

33.00

26.00

26.92%

Operating Profit (PBDIT) excl Other Income

-111.00

-140.00

20.71%

Interest

2.00

3.00

-33.33%

Exceptional Items

0.00

Consolidate Net Profit

-106.00

-135.00

21.48%

Operating Profit Margin (Excl OI)

-3,454.50%

-5,461.50%

200.70%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 26.92% vs -83.75% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 21.48% vs 0.00% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

247.00

258.00

-4.26%

Operating Profit (PBDIT) excl Other Income

-376.00

-300.00

-25.33%

Interest

8.00

4.00

100.00%

Exceptional Items

0.00

-20.00

100.00%

Consolidate Net Profit

-353.00

-283.00

-24.73%

Operating Profit Margin (Excl OI)

-1,562.80%

-1,201.60%

-36.12%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -4.26% vs 120.51% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -24.73% vs 7.82% in Dec 2024

All Annual Results

Company CV

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc.

Pharmaceuticals & Biotechnology

Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapy. The Company has developed drug discovery capability designed to create differentiated small molecules, which has the ability to develop in combinations with its monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. The Company is focused on creating, developing and commercializing differentiated combination cancer therapies that have the potential to cure. The Company has four clinical-stage investigational products: AB928, AB154, Zimberelimab and AB680.

Company Coordinates

Company Details

3928 Point Eden Way , HAYWARD CA : 94545-3719

Tel: 1 510 6946200

https://www.arcusbio.com/

Registrar Details